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Abstract
Epidemiological, clinical, and experimental animal studies suggest a strong correlation
between insulin resistance and Alzheimer’s disease. In fact, type-2 diabetes is considered
an important risk factor of developing Alzheimer’s disease. In addition, impaired insulin sig-
naling in the Alzheimer’s disease brain may promote Aβ production, impair Aβ clearance
and induce tau hyperphosphorylation, thereby leading to deterioration of the disease. The
pathological prion protein, PrPSc, deposits in the form of extracellular aggregates and leads
to dementia, raising the question as to whether prion pathogenesis may also be affected by
insulin resistance. We therefore established high-fat diet-induced insulin resistance in
tga20mice, which overexpress the prion protein. We then inoculated the insulin-resistant
mice with prions. We found that insulin resistance in tga20mice did not affect prion disease
progression, PrPSc deposition, astrogliosis or microglial activation, and had no effect on sur-
vival. Our study demonstrates that in a mouse model, insulin resistance does not signifi-
cantly contribute to prion pathogenesis.
Introduction
Type-2 Diabetes (T2D) represents one of the top threats to human health, and currently afflicts
hundreds of millions of people worldwide (http://www.idf.org/diabetesatlas/update-2014).
Diet-induced obesity is thought to be the primary cause of T2D, and insulin resistance is con-
sidered the central clinical characteristic of what has been called the "metabolic syndrome" [1].
Impaired insulin responsiveness in fat, muscle, and liver cells leads to failure of glucose absorp-
tion despite excessive insulin secretion, resulting in hyperglycemia and associated organ dam-
age in T2D patients.
Intriguingly, T2D is also associated with changes in learning, memory, cognitive flexibility
and processing speed [2]. Peripheral insulin resistance has been reported to go along with
impaired glucose metabolism in the brain [3–6]. Unequivocal evidence from epidemiological
studies indicates that T2D and insulin resistance are linked to an increased risk of sporadic Alz-
heimer’s disease (AD), the most prevalent form of dementia affecting the elderly [7–12]. In
addition, impaired insulin signaling in the brain has been observed in both AD patients and
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animal models of AD [13–20]. However, the molecular mechanisms underlying the connection
between insulin resistance and dementia are far from understood.
Extensive studies have been carried out in animal models to delineate the role of insulin
resistance in AD pathogenesis. High-fat diet-induced dysfunction of insulin signaling in rats
reduces expression of brain-derived neurotrophic factor (BDNF) and leads to cognitive
impairment [21]. Wild-type C57BL/6 mice fed with high-fat diet develop insulin resistance in
the brain, associated with increased tau phosphorylation, reduced post-synaptic protein PSD95
and cognitive impairment [22, 23]. Additional mouse models have suggested that defective
brain insulin signaling can accelerate or exacerbate AD pathology by increasing Aβ deposition
(through promotion of its production and/or impairment of its clearance) and inducing tau
hyperphosphorylation, [24–30]. In cynomolgus monkeys, T2D accelerates Aβ pathology by
exacerbating endocytic malfunction [31]. Conversely, Aβ oligomers that accumulate in AD
brains have been reported to inhibit autophosphorylation of insulin receptor, reduce insulin
receptors on plasma membranes, and decrease insulin signaling in neuronal cells [32, 33]. Fur-
thermore, cerebrally derived Aβ can be transported and accumulated in pancreatic β-cells,
thereby triggering islet degeneration and impairing insulin production [28]. Accordingly, the
interaction between AD and insulin resistance may be reciprocal and bidirectional.
Prion diseases are a group of fatal neurodegenerative disorders comprising various veteri-
nary diseases (scrapie, bovine spongiform encephalopathy, chronic wasting disease), as well as
Creutzfeldt-Jakob disease, kuru, Gerstmann-Sträussler-Scheinker disease and fatal familiar
insomnia in humans [34]. Prion diseases are characterized by the extracellular deposition of
PrPSc, an abnormal isoform of the cellular prion protein (PrPC) [35]. Many observations sug-
gest a possible association between insulin signaling and prion disease. For one, insulin treat-
ment enhances PrPC expression in neuronal cell lines, and PrP deficiency results in insulin
signaling impairment and glucose-intolerance [36–38]. Moreover, aberrant insulin receptor
processing and function was observed in prion-infected neuroblastoma cells [39, 40]. Recently,
it has been reported that prion infection also reduces cell surface expression of insulin receptor
and weakens insulin signaling in neuronal cells [41]. Finally, in an animal model of high-fruc-
tose diet-induced insulin resistance, PrPC expression is downregulated [42].
The above studies are tantalizing, but they do not prove a cross-talk between impaired glu-
cose metabolism and the pathogenesis of prion disease. Therefore, we examined the effect of
high-fat diet-induced insulin resistance on prion pathogenesis. We first established insulin
resistance by feeding mice with a high-fat diet for 4 weeks followed by intracerebral inoculation
with prions. Prion pathogenesis in mice suffering from high-fat diet-induced insulin resistance
was indistinguishable from that of control mice on a normal diet in all investigated parameters,
suggesting that insulin resistance does not significantly affect prion pathogenesis.
Material and Methods
Animals & ethical statement
Female tga20mice were maintained in high hygienic grade facility and housed 3 mice per cage
under a 12 h light/12 h dark cycle (from 7 am to 7 pm) at 21±1°C, and fed with either high fat
diet (Research Diets, #D12492) or normal diet and water ad libitum. HFD were changed twice
a week to avoid oily fur or bedding. Body weights were measured weekly. All animal experi-
ments were carried out in strict accordance with the Rules and Regulations for the Protection
of Animal Rights (Tierschutzgesetz and Tierschutzverordnung) of the Swiss Bundesamt für
Lebensmittelsicherheit und Veterinärwesen and were preemptively approved by the Animal
Welfare Committee of the Canton of Zürich (permit # 41/2012).
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Fasting blood glucose and plasma insulin measurement
Mice were first fasted for 6 hours. Before retro-orbital bleeding, mice were anesthetized with
isoflurane. Blood glucose levels were measured by Accu-Chek Aviva test stripes. To test plasma
insulin level, plasma were prepared from the blood and a Rat/Mouse Insulin ELISA kit (Milli-
pore AG, EZRMI-13K) was used to determine the plasma insulin level according to the manu-
facturer’s instruction.
Glucose and insulin tolerance tests
Glucose and insulin tolerance tests were performed according to published guidelines[43]. To
test intraperitoneal glucose tolerance, tga20mice were first fasted for 6 hours. Mice were then
intraperitoneally injected with glucose 1g/kg (Sigma). Blood glucose levels were measured from
the tail vein at 0, 15, 30, 45, 60 and 120 min after glucose injection. Insulin tolerance tests were
performed similarly with a dose 1 IU/kg of human insulin (Sigma). Blood glucose levels from
the tail vein were measured at 0, 15, 30, 45, 60 and 120 min after insulin injection.
RML6 inoculation
Mice were inoculated intracerebrally (i.c) with 30 μl of brain homogenate diluted in PBS with
5% BSA and containing 3 x 5 log LD50 units of the Rocky Mountain Laboratories scrapie strain
(passage 6, thus called RML6). Mice were monitored and actions were taken to minimize ani-
mal suffering and distress according to the details described in S1 Table. Scrapie was diagnosed
according to clinical criteria (ataxia, limb weakness, front leg paresis and rolling). Mice were
sacrificed by CO2 inhalation on the day of appearance of terminal clinical signs of scrapie (spe-
cific criteria in S1 Table), organs were taken and then were either snap-frozen for biochemical
analysis or fixed in 4% formalin for histological assessment. The time elapsed from prion inoc-
ulation to the terminal stage of disease was defined as incubation time for the survival study.
Quantitative real-time PCR (qRT-PCR)
Total RNA from each brain was extracted using TRIzol (Invitrogen) according to the manufac-
turer’s instruction. The quality of RNA was analyzed by Bioanalyzer 2100 (Agilent Technolo-
gies), RNAs with RIN>7 were used for cDNA synthesis. cDNA were synthesized from ~1 μg
total RNA using QuantiTect Reverse Transcription kit (QIAGEN) according to the manufac-
turer’s instruction. Quantitative real-time PCR (qRT-PCR) was performed using the SYBR
Green PCRMaster Mix (Roche) on a ViiA7 Real-Time PCR system (Applied Biosystems).
Expression levels were normalized using Gapdh. The sequence of qRT-PCR primers are:
Gapdh sense, 5´-CCA CCC CAG CAA GGA GAC T-3´;antisense, 5´-GAA ATT GTG AGG
GAG ATG CT-3´. Prnp sense, 5´-GCC AGT GGA TCA GTA CAG CA-3´; antisense, 5´-ATC
CCA CGA TCA GGA AGA TG-3´. TNFα sense, 5´-ACT TCG GGG TGA TCG GTC CCC-3´;
antisense, 5´-TGG TTT GCT ACG ACG TGG GCT AC-3´. IL-6 sense, 5´-TCC AAT GCT
CTC CTA ACA GAT AAG-3´; antisense, 5´-CAA GAT GAA TTG GAT GGT CTT G-3´.; IL-
1β sense, 5´-TGC AGC TGG AGA GTG TGG ATC CC-3´; antisense, 5´-TGT GCT CTG CTT
GTG AGG TGC TG-3´.
Western blot analysis
To detect PrPC in the mouse brains, one hemisphere of each brain was homogenized with
buffer PBS containing 0.5% Nonidet P-40 and 0.5%CHAPSO. Total protein concentration was
determined using the bicinchoninic acid assay (Pierce). ~8 ug proteins were loaded and sepa-
rated on a 12% Bis-Tris polyacrylamide gel (NuPAGE, Invitrogen) and then blotted onto a
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nitrocellulose membrane. Membranes were blocked with 5% wt/vol Topblock (LuBioScience)
in PBS supplemented with 0.1% Tween 20 (vol/vol) and incubated with primary antibodies
POM1 in 1% Topblock (400 ng ml−1) overnight. After washing, the membranes were then
incubated with secondary antibody horseradish peroxidase (HRP)-conjugated rabbit anti–
mouse IgG1 (1:10,000, Zymed). Blots were developed using Luminata Crescendo Western
HRP substrate (Millipore) and visualized using the Stella system (model 3000, Bio-Rad). To
avoid variation in loading, the same blots were striped and incubated with anti-actin antibody
(1:10,000, Millipore). The PrPC signals were normalized to actin as a loading control. Similar
protocol was used for Western blot to detect pSer473-Akt and total Akt, pSer9-GSK3β and total
GSK3β. The primary antibodies used were Phospho-Akt (Ser473) (D9E) XP1 Rabbit mAb
(Cell Signaling Technology, 4060), Akt (pan) (11E7) Rabbit mAb (Cell Signaling Technology,
4685), Phospho-GSK-3-beta (Ser9) (D3A4) Rabbit mAb (Cell Signaling Technology, 9322),
GSK3β (27C10) Rabbit mAb (Cell Signaling Technology, 9315). The secondary antibody used
was HRP-conjugated goat anti–rabbit IgG1 (1:10,000, Jackson ImmunoResearch, 115-035-
045)
To detect PrPSc, prion infected forebrains were homogenized in sterile 0.32 M sucrose in
PBS. Total protein concentration was determined using the bicinchoninic acid assay (Pierce).
Samples were adjusted to 20 μg protein in 20 μl and digested with 50 μg ml−1 proteinase K in
digestion buffer (PBS containing 0.5% wt/vol sodium deoxycholate and 0.5% vol/vol Nonidet
P-40) for 45 min at 37°C. PK digestion was stopped by adding loading buffer (Invitrogen) and
boiling samples at 95°C for 5 min. Proteins were then separated on a 12% Bis-Tris polyacryl-
amide gel (NuPAGE, Invitrogen) and blotted onto a nitrocellulose membrane. POM1 and
horseradish peroxidase (HRP)-conjugated rabbit anti–mouse IgG1 were used as primary and
secondary antibodies, respectively. Blots were developed using Luminata Crescendo Western
HRP substrate (Millipore) and visualized using the FUJIFILM LAS-3000 system. To detect
IBA-1 and GFAP in prion-infected brains by Western blot, 20 μg of total brain protein were
loaded and anti-IBA-1 antibody (1:1000; Wako Chemicals GmbH, Germany) anti-GFAP anti-
body (D1F4Q) XP1 Rabbit mAb (1:3000; Cell Signaling Technology, 12389) were used. Actin
was used as loading control.
Enzyme-linked Immunosorbent Assay (ELISA)
PrPC in ND- or HFD- fed mouse brains was quantified by sandwich ELISA as described previ-
ously[44]. Briefly, 96-well plates were coated with 400ng/ml of purified POM1 antibodies over-
night at 4°C. Plates were washed with PBS containing 0.1% (vol/vol) Tween 20 (PBST), and
blocked with 5% TopBlock for 2hrs at room temperature. After washing, plates were incubated
with 50 ul of serially diluted samples in PBST containing 1% TopBlock, starting from a 50ug/
ml dilution. After 2hrs at room temperature, plates were washed extensively and then probed
with biotinylated POM2 at a concentration of 200ng/ml in PBST containing 1% TopBlock for
1hr at room temperature. Subsequently, plates were washed and incubated with horseradish
peroxidase conjugated Avidin (1:1000 dilution, Pharmingen No. 554058) for 1hr at room tem-
perature. Plates were developed with TMB (3,3', 5,5;-tetramethylbenzidine) for 15–30min and
stopped by adding 0.5M H2SO4, and optical density was measured at 405nm. Titer was defined
as the highest dilution showing an ODmore than two times the technical background, which
was calculated as the average of uncoated wells.
Immunohistochemistry
Formalin-fixed tissues were treated with concentrated formic acid for 60 min to inactivate
prion infectivity and embedded in paraffin. Paraffin sections (2mm) of brains were stained
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with hematoxylin/eosin (HE). After deparaffinization through graded alcohols, antibodies
GFAP (1:300; DAKO, Carpinteris, CA) for astrocytes were applied and visualized using stan-
dard methods, IBA-1 (1:1000; Wako Chemicals GmbH, Germany) was used for highlighting
activated microglial cells. Stainings were visualized using DAB (Sigma-Aldrich), with a hema-
toxylin counterstain applied subsequently. For partially protease K-resistant prion protein
deposition staining, deparaffinized sections were incubated for 6 min in 98% formic acid and
washed in distilled water for 30 min. Sections were incubated in Ventana buffer and stains
were performed on a NEXEX immunohistochemistry robot (Ventana instruments, Switzer-
land) using an IVIEW DAB Detection Kit (Ventana). After incubation with protease 1
(Ventana) for 16 min, sections were incubated with anti-PrP SAF-84 (SPI bio, A03208, 1:200)
for 32 min. Sections were counterstained with hematoxylin. Sections were imaged using a Zeiss
Axiophot light microscope.
Statistical analysis
Results are presented as the mean of replicas ± standard error of the mean (SEM). Statistical
significance between experimental groups was assessed using an unpaired Student’s t-Test or
two-way analysis of variance (ANOVA). Incubation times were analyzed using the Kaplan-
Meier method and compared between groups using the logrank test. p-values<0.05 were con-
sidered statistically significant.
Results
High-fat diet-induced insulin resistance in tga20 mice
High-fat diet (HFD) induced insulin resistance has been well-established in various inbred
mouse strains [45–48]. The success of insulin resistance induction by diet is highly dependent
on the mouse genetic background [46, 47]. In order to induce insulin resistance in tga20mice,
a transgenic line that overexpress prion protein and was generated on a 129Sv x C57BL/6
genetic background [49], 6–8 weeks old female tga20mice were fed with either a HFD contain-
ing 60% kcal from fat, or with a normal diet (ND) consisting of 10% kcal from fat (n = 6 per
group). Body weight was measured weekly. After 4 weeks, the HFD treated group showed sig-
nificantly higher body weights than ND group, and HFD fed mice show obesity (Fig 1A). Fast-
ing blood glucose and plasma insulin levels were also compared between HFD and ND groups.
While fasting glucose level was not obviously different between these two groups, fasting insu-
lin level was significantly increased in HFD group (Fig 1B), indicating that hyperinsulinemia
had been attained in tga20mice after 4 weeks of treatment.
We next performed intraperitoneal glucose and insulin tolerance tests on tga20mice after 4
weeks of a HFD or ND. The HFD-treated tga20mice showed impaired glucose and insulin tol-
erance compared to mice fed with a ND (Fig 1C and 1D). Therefore, 4 weeks of HFD feeding is
sufficient to induce insulin resistance in tga20mice. Taken together, these data indicate that
HFD treatment on tga20mice for 4 weeks resulted in obesity, hyperinsulinemia and insulin
resistance.
Dysregulated insulin signaling but unchanged PrPC expression in the
brains of tga20 mice on a high-fat diet
Peripheral insulin resistance is often associated with impaired insulin signaling and dysregu-
lated glucose metabolism in the brain [3–6]. We therefore sought to determine whether HFD
feeding led to dysregulation of insulin signaling in tga20mouse brain. We first assessed the lev-
els of Ser473-phosphorylated Akt (pSer473-Akt) which is downstream of insulin signaling and
Insulin Resistance and Prion Disease
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Fig 1. High-fat diet induced insulin resistance in tga20mice. (A) Left: Body weight of tga20mice fed with either high-fat diet (HFD) or normal diet (ND).
After 4 weeks, HFD-fed mice gained significantly more body weight than ND-fed mice after 4 weeks. (n = 6; ***: p<0.001). Right: appearance of mice fed
with ND or HFD for 4 weeks. (B) Fasting glucose and insulin level in HFD-fed and ND-fed mice. HFD-fed mice had similar levels of fasting glucose, but
showed significantly higher fasting insulin levels. (n = 6; n.s: p>0.05; **: p<0.01). (C) glucose tolerance test and (D) insulin tolerance test of HFD-fed and ND-
fed mice. HFD-fed mice showed impaired response to intraperitoneally injected glucose and insulin (n = 6; ***: p<0.001; ****: p<0.0001).
doi:10.1371/journal.pone.0144983.g001
Insulin Resistance and Prion Disease
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phosphorylated by PI3K. We found that the level of pSer473-Akt was significantly lower (,
p = 0.028) in HFD group, suggesting an impairment of insulin signaling in HFD brains (Fig 2A
and S1 Fig). We also measured the level of pSer9-GSK3β, a form of GSK3β phosphorylated by
activated Akt. We observed a trend of reduced level of pSer9-GSK3β (n.s, p = 0.0890) in the
HFD group (Fig 2B and S2 Fig), suggesting that insulin signaling in HFD fed mouse brain was
indeed impaired.
The level of cellular prion protein (PrPC) is the main determinant of the speed of prion
pathogenesis. A 50% reduction of PrPC expression, e.g. brought about by hemizygosity in the
Prnp gene, conspicuously prolongs prion incubation time [50]. Conversely, overexpression of
PrPC remarkably accelerates prion progression [49]. It was reported that high-fructose diet-
induced insulin resistance reduces PrPC expression in rats [42]. We therefore assessed whether
HFD treatment affects PrPC expression. However, qRT-PCR for Prnp transcripts, Western blot
and ELISA for PrPC altogether showed that PrPC expression was not changed by HFD treat-
ment (Fig 2C–2E).
Unaltered prion pathogenesis in insulin resistant tga20 mice
Having established insulin resistance in tga20mice, we further evaluated the effect of insulin
resistance on prion pathogenesis. Tga20mice were first fed with HFD for 4 weeks to induce
insulin resistance. Next, HFD-fed or ND-fed control tga20mice were inoculated intracerebrally
(i.c) with RML6. The ND vs. HFD feeding was maintained in the respective groups throughout
the entire experimental period. The incubation time was defined as the time elapsed from
prion inoculation to the terminal stage of disease (the day on which mice showed severe scrapie
symptoms requiring euthanasia). We found that both HFD and ND fed groups succumbed to
prion disease with similar incubation times (ND: median survival = 63 dpi, HFD: median sur-
vival = 65.5 dpi; p = 0.307) (Fig 3A), suggesting that HFD-induced insulin resistance does not
significantly contribute to the prion progression. No unexpected death was observed in this
study.
Next, we assessed proteinase K-resistant PrPSc deposition in terminally sick mouse brains.
Western blots revealed that there were similar PrPSc levels in the HFD and ND groups (Fig
3B). Histological analysis of terminally sick mouse brains also demonstrated that HFD treat-
ment does not alter prion pathology, as spongiform changes were qualitatively similar in the
two groups (Fig 3C).
Astrogliosis and microglial activation are both associated with prion pathogenesis. Immu-
nohistochemical staining of the astrocyte marker GFAP and microglial marker Iba1 showed
similar levels of astrogliosis and microglial activation in terminally sick mice fed witht HFD or
ND (Fig 4A). The latter findings were further confirmed by Western blot of GFAP and Iba1 for
brains from terminally sick HFD- and ND-fed mice (Fig 4B and 4C). Cytokine profiling of ter-
minally sick mouse brains also failed to reveal an obvious difference between HFD and ND
groups (Fig 4D). Overall, we conclude that insulin resistance does not alter prion progression,
PrPSc deposition, astrogliosis and microglial activation.
Fig 2. Dysregulated insulin signaling but unchanged PrPC expression in HFD-fedmouse brains. (A) Left: Western blot of pSer473-Akt and total Akt in
ND- or HFD-fed mouse brains. Right: densitometric quantification of the Western blot showed significantly lower pSer473-Akt/Akt ratio in HFD-fed mouse
brains (n = 3, *, p = 0.0280) (B) Left: Western blot of pSer9-GSK3β and total GSK3β in ND- or HFD-fed mouse brains. Right: densitometric quantification of the
Western blot revealed a trend of reduced lower pSer9-GSK3β/ GSK3β ratio in HFD-fed mouse brains (n = 3, n.s p = 0.0890). (C) qRT-PCR of Prnp expression
in HFD-fed and ND-fed mouse brains showed similar levels of PrnpmRNA (n = 3, n.s p>0.05). (D) Left: Western blot of PrPC in HFD-fed and ND-fed mouse
brains. Right: densitometric quantification of the Western blot demonstrated a similar level of PrPC expression (n = 3, n.s p>0.05). (E) ELISA of PrPC showed
similar level of PrPC expression in HFD-fed and ND-fed mouse brains (n = 3, n.s p>0.05).
doi:10.1371/journal.pone.0144983.g002
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Discussion
Increasing evidence from epidemiological and clinical studies suggests that impaired insulin
signaling is linked to neurodegeneration [7–12]. Specifically, reduced insulin level and insulin
activity may contribute to the pathological processes associated with AD. Experimental studies
using mouse models of AD and diet-induced insulin resistance suggest several molecular path-
ways by which insulin resistance may aggravate AD pathology [24–30]. Therefore, supplemen-
tation of insulin to the brain may provide therapeutic potential benefits to AD patients. Indeed,
intranasal administration of insulin to AD patients has been shown to modulate plasma Aβ lev-
els, enhance memory and improve cognition [51–55]. These encouraging results prompted us
to explore whether insulin administration could also benefit other neurodegenerative diseases.
We therefore aimed to determine the effect of insulin resistance in prion pathogenesis.
We first introduced a high-fat diet regime, which is well-established and widely used to
induce insulin resistance in rodents, to tga20mice, a transgenic mouse line overexpressing
PrPC that reliably experiences prion pathogenesis with rapid progression upon infection. Four
weeks of high-fat diet is sufficient to induce insulin resistance, as evidenced by obesity, hyper-
insulinemia and impaired glucose and insulin tolerance. The extent of insulin resistance in the
model established here was not qualitatively different from other models using wild-type mice
[22, 23]. In line with previous reports [24–30], HFD-induced insulin resistance was also associ-
ated with impaired insulin signaling in the brain. We then inoculated the insulin resistant
tga20mice with prions. Interestingly, high-fat diet-fed tga20mice displayed similar prion pro-
gression and pathogenesis to that of normal diet-fed tga20mice, suggesting insulin resistance
does not alter prion-induced neurotoxicity, PrPSc deposition and neuroinflammation. The
absence of an effect of insulin resistance on prion pathogenesis also indicates that distinct cellu-
lar and molecular pathways are employed by PrPSc and Aβ for accumulation and clearance.
The use of tga20 transgenic mice may be viewed as a possible limitation of the present study.
These mice ovexpress the prion protein and experience a much more rapid pathogenesis of
scrapie than wild-type mice. However, it is conceivable that the natural course of scrapie in
tga20mice may differ from that of wild-type mice. We deem the use of tga20mice justifiable
and informative in this context for several reasons. Firstly, a wealth of studies with tga20mice
has failed to uncover any relevant deviation from wild-type mice in pathogenesis, except for
the vastly shortened incubation times [49, 56–61]. Secondly, the susceptibility of tga20mice to
prions and even their prion titers at the terminal stage of disease are similar to those of wild-
type mice[49, 62]. Thirdly, both a hemizygous Prnp allele and the tga20 transgene was found to
suppress both the granule-cell degeneration of Dpl-overexpressing mice and the chronic demy-
elinating peripheral neuropathy of Prnp-/- mice[63, 64], indicating that the tga20 allele is func-
tionally indistinguishable from its wild-type counterpart. The only deviation that was recorded
in tga20mice is a lack of PrPC expression in cerebellar Purkinje cells[49, 63, 65], possibly due
to the absence of a relevant intragenic promoter element (a phenomenon that is not expected
to play a role in the studies presented here).
We have found that transcription of the Prnp transgene was unaffected by the high-fat diet.
This finding is at odds with a previous study using rats subjected to a high-fructose diet [42].
This discrepancy may be due to different diet regimes or to the different animal species.
Fig 3. Unaltered prion pathogenesis in HFD-fed tga20mice. (A) Survival curve of HFD-fed and ND-fed tga20mice intracerebrally inoculated with RML6.
There was no significant difference in survival between the two groups (n = 6 per group; n.s.: p>0.05). (B) Left: Western blot for proteinase K resistant PrPSc
in terminally sick mouse brains. Right: densitometric quantification of theWestern blot revealed no significant difference between HFD-fed and ND-fed tga20
mouse brains (n = 3, n.s p>0.05). (C) Representative histology of terminally sick HFD-fed and ND-fed tga20mouse brains stained for H&E and SAF84. There
was no obvious difference between the two groups in lesion pattern, vacuolation, and PrPSc deposition. Scale bar = 200μm.
doi:10.1371/journal.pone.0144983.g003
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Additionally, the tga20 allele is controlled by a Prnpminigene that does not contain the entirety
of the endogenous Prnp regulatory sequences, and reverberations of impaired insulin signaling
onto the transcription of endogenous Prnpmay lead to effects undetectable in the experiments
described here. However, such a scenario would not apply to modulation of PrPSc aggregation
and/or clearance. Therefore, despite this caveat, our study demonstrates that in contrast to AD
or mouse models of AD, insulin resistance does not obviously affect prion pathogenesis. These
results indicate that the relationship of insulin resistance between to prions is much blander
than that to AD, and are in line with the absence of obvious epidemiological evidence of predis-
position to prion disease in T2D patients. Conversely, these data should not be taken to suggest
that targeting certain pleiotropic components associated with insulin pathway, such as mTOR
and AMPK, would necessarily exert no effects on the pathogenesis of prion diseases.
Supporting Information
S1 Fig. (A) Left: Original uncroppedWestern blots of pSer473-Akt in ND- or HFD-fed
mouse brains. Arrow indicates the specific pSer473-Akt band, unspecific bands are indicated
as . Right: Western blot of Actin for loading control. (B) Left: Original uncropped West-
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Fig 4. Similar level of astrogliosis andmicroglial activation in terminally sick HFD- and ND-fed tga20
mice. (A) Representative immunohistochemical staining for GFAP and Iba1 in brains of terminally sick HFD-
fed and ND-fed tga20mice. There was no detectable difference between the two groups in astrogliosis or
microglial activation. Scale bar = 100μm. (B) Left: Western blot for Iba1 in terminally sick mouse brains. Right:
densitometric quantification of the Western blot revealed no significant difference of Iba1 levels between
HFD-fed and ND-fed tga20mouse brains (n = 3; n.s.: p>0.05). (C) Left: Western blot for GFAP in terminally
sick mouse brains. Right: densitometric quantification of the Western blot showed no significant difference of
GFAP levels between HFD-fed and ND-fed tga20mouse brains (n = 3; n.s.: p>0.05). (D) qRT-PCR of
cytokines TNFα, IL-6 and IL-1β expression revealed similar expression levels of these cytokines in terminally
sick HFD-fed and ND-fed mouse brains (n = 3; n.s.: p>0.05).
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